Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
M. Donaghy (Belfast, United Kingdom), C. Addy (Belfast, United Kingdom), J. Mclornan (Belfast, United Kingdom), O. Hewitt (Belfast, United Kingdom), R. Redfern (Belfast, United Kingdom), D. Downey (Belfast, United Kingdom), S. Caskey (Belfast, United Kingdom). The clinical impact of nebulised antibiotics in adults with bronchiectasis and chronic pseudomonas aeruginosa. 2369

Member's Comments

No comment yet.

Related content which might interest you: Non-CF bronchiectasis: nebulised colistimethate sodium improves symptoms and bacterial load in sputum of patients with pseudomonas aeruginosa Source: Annual Congress 2008 - Microbiology and treatment of bronchiectasis and exacerbations of COPD Year: 2008 Inhaled colistin in elderly patients with bronchiectasis and chronic bronchial infection with pseudomonas Source: Annual Congress 2012 - Management of severe respiratory infections Year: 2012 Pseudomonas aeruginosa drug susceptibility in patients hospitalized with COPD exacerbation and bronchiectasis Source: Eur Respir J 2001; 18: Suppl. 33, 541s Year: 2001 Nebulized antibiotics in patients with non-cystic fibrosis bronchiectasis ans chronic pseudomonas aeruginosa infection Source: Annual Congress 2011 - Pseudomonas aeruginosa infection and non-cystic fibrosis bronchiectasis Year: 2011 Azithromycin in chronic respiratory infections with pseudomonas aeruginosa in patients without cystic fibrosis Source: Annual Congress 2008 - Mechanisms of respiratory infections: interaction between the pathogen and the host Year: 2008 The impact of pseudomonas aeruginosa in the sputum of patients presenting with acute COPD exacerbation Source: Annual Congress 2004 - Role of infection in COPD Year: 2004 Eradication treatment in Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) on patients with pseudomonas aeruginosa Source: International Congress 2017 – Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections Year: 2017 Inhaled colistin in patients with non - cystic fibrosis bronchiectasis and chronic pseudomonas aeruginosa bronquial infection Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations Year: 2016 Pseudomonas aeruginosa and antibiotic resistance in acute exacerbations of COPD (AECOPD) Source: Annual Congress 2009 - Respiratory infection caused by Pseudomonas aeruginosa Year: 2009 Acute exacerbations of COPD due to pseudomonas aeruginosa: Impact of antimicrobial resistance Source: International Congress 2015 – Infection in COPD: different aspects of the host/pathogen balance Year: 2015 The effect of tobramycin nebulised solution in COPD patients with Pseudomonas aeruginosa in sputum (preliminary report) Source: Eur Respir J 2004; 24: Suppl. 48, 409s Year: 2004 Efficacy of ciprofloxacin against resistant mucoid or non-mucoid P. aeruginosa isolated from non-cystic fibrosis bronchiectasis (NCFB) patients considering lung pharmacokinetics after ciprofloxacin DPI treatment Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 The effect of nebulised colistimethate sodium on non-CF bronchiectasis with pseudomonas aeruginosa (preliminary report) Source: Eur Respir J 2007; 30: Suppl. 51, 439s Year: 2007 Effectiveness of inhaled colistin by iNeb® device in non-CF bronchiectasis and chronic pseudomonas infection Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical and functional characterisation Year: 2015 The effect of erythromycin on the chronic lower airway infection by pseudomonas aeruginosa Source: Eur Respir J 2004; 24: Suppl. 48, 640s Year: 2004 Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study Source: Eur Respir J 2013; 41: 1107-1115 Year: 2013 Highly concentrated aerosolized tobramycin in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection Source: Eur Respir J 2005; 26: Suppl. 49, 620s Year: 2005 Inhaled corticosteroid use and its association with Pseudomonas aeruginosa infection in COPD Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies Year: 2021 Efficacy of low-dose, long-term clarithromycin administration in improving the clinical course in cystic fibrosis patients with chronic P. aeruginosa airway colonization Source: Eur Respir J 2003; 22: Suppl. 45, 514s Year: 2003 The efficacy of macrolides in the treatment of bronchiectasis colonised by Ps aeruginosa Source: Eur Respir J 2004; 24: Suppl. 48, 638s Year: 2004